[Tickers Inside] 7 Solid Gainers Over the Last 5 Sessions

Stocks with 5 days of consecutive price advances. If you cannot see this email properly, please click [here]( [9k=] --------------------------------------------------------------- ["White Gold" is the New Oil]( [Read this free report before it gets the attention of Wall Street.]([aff_i?offer_...] --------------------------------------------------------------- August 18, 2022 From the desk of the Editor (5 Day Gainers Report) Dear Reader, We just identified 7 Five Day Gainers of all US Exchanges. If you are interested in any of these companies, we encourage you to do your own research and due diligence. Keep reading to see what we just uncovered... --------------------------------------------------------------- [Want To Catch The Next Hot Investing Trend (Look Inside?)]( [fd3445f6-138...](While millennials are trying to get rich in crypto Ponzi schemes- there's something happening that Wall Street is TOTALLY ignoring. And it's about to affect every American Citizen over 55... [And It Could Spark An Economic Boom For American Investors]( [5381a560-c43...]( [aff_i?offer_...] --------------------------------------------------------------- [BioVie, BIVI]( Recent Analyst Action: Mayank Mamtani, analyst at B.Riley Financial, reiterates coverage on [BioVie (BIVI)](in the Healthcare sector with a Buy rating and a price target of $12 (3 weeks ago). - Recent Price: $3.15 - Average Analyst Price Target: $9.50 (201.59%) - Market Cap: $74.68M [TipRanks.com]( also reports that [BioVie](currently has 2 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $9.50. The target pricing ranges from a high forecast of $12.00 down to a low forecast of $7.00. [BioVie (BIVI)](’s last closing price was $3.15 which would put the average price target at $9.50. Here are 3rd party ratings for [BIVI](: - TipRanks.com: Moderate Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Weak sell - Zacks.com: Hold, Top 29% (72 out of 252) [Click here for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- [Hidden $5 Stock Holds Tech World Hostage]( [19cee239-162...](Tech monsters like Apple, Amazon, Microsoft and many more can no longer avoid doing business with [this one company that trades for only $3](... All of them are held hostage by the CEO's brilliant business tactics. And what's even crazier... Is that his tactics reach all the way to the public. He intentionally set up his company's stock under a [secret trade name.](.. Did he fool you too? [Click here to see more.]( [5381a560-c43...]( [aff_i?offer_...] --------------------------------------------------------------- [MoonLake Immunotherapeutics, MLTX]( Recent Analyst Action: Ram Selvaraju, analyst at H.C. Wainwright, reiterates coverage on [MoonLake Immunotherapeutics (MLTX)](in the Healthcare sector with a Buy rating and a price target of $28 (3 days ago). - Recent Price: $8.22 - Average Analyst Price Target: $28.00 (240.63%) - Market Cap: $444.80M [TipRanks.com]( also reports that [MoonLake Immunotherapeutics](currently has 2 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $28.00. The target pricing ranges from a high forecast of $28.00 down to a low forecast of $28.00. [MoonLake Immunotherapeutics (MLTX)](’s last closing price was $8.22 which would put the average price target at $28.00. Here are 3rd party ratings for [MLTX](: - TipRanks.com: Moderate Buy - TradingView.com: Buy - Yahoo! Finance: Neutral Short-Term Outlook - Barchart.com: Weak buy - Zacks.com: Hold, Top 27% (68 out of 252) [Click here for chart >>]( -------------------------------------------------------------------------- [Altus Power, AMPS]( Recent Analyst Action: Stephen Byrd, analyst at Morgan Stanley, reiterates coverage on [Altus Power (AMPS)](in the Utilities sector with a Hold rating and a price target of $12.5 (11 hours ago). - Recent Price: $11.64 - Average Analyst Price Target: $11.90 (2.23%) - Market Cap: $1.72B [TipRanks.com]( also reports that [Altus Power](currently has 5 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $11.90. The target pricing ranges from a high forecast of $15.00 down to a low forecast of $10.00. [Altus Power (AMPS)](’s last closing price was $11.64 which would put the average price target at $11.90. Here are 3rd party ratings for [AMPS](: - TipRanks.com: Moderate Buy - TradingView.com: Strong Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Strong buy - Zacks.com: Buy, Top 27% (68 out of 252) [Click here for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast: ["Prepare for Five Years of Famine"]( [Screen+Shot+...]( [Click here]( for the name of the one ticker you need to protect yourself.[5381a560-c43...]([aff_i?offer_...] --------------------------------------------------------------- [Amtech Systems, ASYS]( Recent Analyst Action: Mark Miller, analyst at Benchmark Co., reiterates coverage on [Amtech Systems (ASYS)](in the Industrial Goods sector with a Buy rating and a price target of $18 (2 days ago). - Recent Price: $10.78 - Average Analyst Price Target: $18.00 (66.98%) - Market Cap: $142.64M [TipRanks.com]( also reports that [Amtech Systems](currently has 1 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $18.00. The target pricing ranges from a high forecast of $18.00 down to a low forecast of $18.00. [Amtech Systems (ASYS)](’s last closing price was $10.78 which would put the average price target at $18.00. Here are 3rd party ratings for [ASYS](: - TipRanks.com: Moderate Buy - TradingView.com: Buy - Yahoo! Finance: Neutral Short-Term Outlook - Barchart.com: Weak buy - Zacks.com: Hold, Bottom 31% (174 out of 252) [Click here for chart >>]( -------------------------------------------------------------------------- [Reneo Pharmaceuticals, RPHM]( Recent Analyst Action: Brian Skorney, analyst at Robert W. Baird, reiterates coverage on [Reneo Pharmaceuticals (RPHM)](in the Healthcare sector with a Buy rating and a price target of $28 (1 week ago). - Recent Price: $3.27 - Average Analyst Price Target: $21.50 (557.49%) - Market Cap: $79.73M [TipRanks.com]( also reports that [Reneo Pharmaceuticals](currently has 3 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $21.50. The target pricing ranges from a high forecast of $28.00 down to a low forecast of $15.00. [Reneo Pharmaceuticals (RPHM)](’s last closing price was $3.27 which would put the average price target at $21.50. Here are 3rd party ratings for [RPHM](: - TipRanks.com: Strong Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: hold - Zacks.com: Buy, Top 29% (72 out of 252) [Click here for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- [Investor Alert: Argentina Loaded With "White Gold" Opportunity]( [68521814-32c...](Experts expect the global lithium market to grow by 500% due to the explosion of electric vehicles and green energy. And one small-cap company just snagged a large lithium deposit in a renowned South American location. [Read about this company's once-in-a-lifetime lithium opportunity -- before Wall Street takes notice.]( [5381a560-c43...]([aff_i?offer_...] --------------------------------------------------------------- [Werewolf Therapeutics, HOWL]( Recent Analyst Action: Andres Y., analyst at H.C. Wainwright, reiterates coverage on [Werewolf Therapeutics (HOWL)](in the Healthcare sector with a Buy rating and a price target of $20 (6 days ago). - Recent Price: $6.12 - Average Analyst Price Target: $20.00 (226.80%) - Market Cap: $170.63M [TipRanks.com]( also reports that [Werewolf Therapeutics](currently has 1 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $20.00. The target pricing ranges from a high forecast of $20.00 down to a low forecast of $20.00. [Werewolf Therapeutics (HOWL)](’s last closing price was $6.12 which would put the average price target at $20.00. Here are 3rd party ratings for [HOWL](: - TipRanks.com: Moderate Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Weak buy - Zacks.com: Hold, Top 27% (68 out of 252) [Click here for chart >>]( -------------------------------------------------------------------------- [Encore Wire, WIRE]( Recent Analyst Action: Brent Thielman, analyst at D.A. Davidson, reiterates coverage on [Encore Wire (WIRE)](in the Industrial Goods sector with a Buy rating and a price target of $190 (3 weeks ago). - Recent Price: $143.88 - Average Analyst Price Target: $190.00 (32.05%) - Market Cap: $2.57B [TipRanks.com]( also reports that [Encore Wire](currently has 1 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $190.00. The target pricing ranges from a high forecast of $190.00 down to a low forecast of $190.00. [Encore Wire (WIRE)](’s last closing price was $143.88 which would put the average price target at $190.00. Here are 3rd party ratings for [WIRE](: - TipRanks.com: Moderate Buy - TradingView.com: Strong Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: buy - Zacks.com: Strong Buy, Top 1% (1 out of 252) [Click here for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- [Could Biden's Executive Order 14017 Trigger A BULL RUN For This Little-Known Industry?]( [a4f92c65-722...](You've never heard of this rare metal. But it's CRITICAL for our fighter jets, missiles, and military vehicles. The bad news is, Communist China has a MONOPOLY on this critical resource... [But Trump AND Biden's Executive Orders Could Change That, And Trigger A Boom For Investors](//trailer.web-view.net/Links/0XD6B7C0068FEF23BB6A8BC35F6C347824FDAAA18B1B3D1A7A50AA4593A8E7E9AF0B715760693428632C62457C814201B2F903C0F29FECF48F97B78C110EC8F65BF598CD369566B7DD.htm [5381a560-c43...]( [aff_i?offer_...] --------------------------------------------------------------- And there you have it--7 Five Day Gainers of all US Exchanges. Sincerely, Editor, MarketMoversInsider.com Disclaimer This email/newsletter contains advertisements which are neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this email/newsletter is not provided to any individual with a view toward their individual circumstances. Compensation for advertising constitutes a conflict of interest as to our ability to remain objective in our communication regarding any companies profiled. Because of this conflict, individuals are strongly encouraged to not use this email/newsletter as the basis for any investment decision. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our email/newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. MarketMoversInsider.com | PO Box 407 | Mt. Mourne | North Carolina | 28123 | United States | 8458030954 [Unsubscribe]( | [Report spam]( Sent with [ActiveTrail]( software